Which stock wins in a matchup between a gene sequencing pioneer and a fast-rising liquid biopsy leader?
News & Analysis: Illumina
The DNA sequencing pioneer promised a $1,000 human genome by early 2019. The price isn't so important, but the technology upgrades will prove critical.
They're pioneers. They're innovators. And they should continue to be huge winners for investors with long-term perspectives.
Each of these healthcare companies takes a different approach to fighting cancer, but all have what it takes to be long-term winners in your portfolio.
Growth stagnated in the first half of 2019. Management says it will be temporary.
Are the disappointing results for Illumina a "new normal"? Not at all, according to its top executives.
ILMN earnings call for the period ending June 30, 2019.
The genomic sequencing company reported slower revenue growth because of several issues, including a delay in closing a major population genomics deal.
Market caps for these medical device stocks are big. Most of them have been big winners, too.
Abandoning the proposed deal would have a seismic effect on the future of DNA sequencing, but it's not all bad news for investors.